<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VETROMAX- gentamicin sulfate, betamethasone valerate and clotrimazole ointment </strong><br>Dechra Veterinary Products<br></p></div>
<h1>VETROMAX<span class="Sup">®</span><br> gentamicin sulfate USP, betamethasone valerate USP and clotrimazole USP ointment</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="SPDES"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">VETERINARY</span></p>
<p><span class="Bold">ANADA</span># 200-283. Approved by FDA.</p>
<p>For otic use in dogs only.</p>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="section-2"></a><p></p>
<h1>CAUTION:</h1>
<p class="First"><span class="Bold">Federal law restricts this drug to use by or on the order of a licensed veterinarian.</span></p>
<p><span class="Bold">Keep this and all drugs out of the reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">
Each gram of Vetromax ointment contains gentamicin sulfate USP equivalent
to 3 mg gentamicin base; betamethasone valerate USP equivalent to 1 mg betamethasone; and
10 mg clotrimazole USP in a mineral oil-based system containing a plasticized hydrocarbon gel.
<br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>PHARMACOLOGY:</h1>
<p class="First"><span class="Bold">Gentamicin:</span> Gentamicin sulfate is an aminoglycoside antibiotic active against a wide variety of
pathogenic gram-negative and gram-positive bacteria. <span class="Italics">In vitro</span> tests have determined that
gentamicin is bactericidal and acts by inhibiting normal protein synthesis in susceptible
microorganisms. Specifically, gentamicin is active against the following organisms commonly
isolated from canine ears: <span class="Italics">Staphylococcus aureus,</span> other <span class="Italics">Staphylococcus</span> spp., <span class="Italics">Pseudomonas
aeruginosa, Proteus</span> spp., and <span class="Italics">Escherichia coli.</span></p>
<p><span class="Bold">Betamethasone: </span>Betamethasone valerate is a synthetic adrenocorticoid for dermatologic use.
Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a
slight degree of mineralocorticosteroid activity. Betamethasone valerate, the 17-valerate ester of
betamethasone, has been shown to provide anti-inflammatory and antipruritic activity in the
topical management of corticosteroid-responsive <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>.<br>
Topical corticosteroids can be absorbed from normal, intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> can increase
percutaneous absorption. Once absorbed through the skin, topical corticosteroids are handled
through pharmacokinetic pathways similar to systemically administered corticosteroids.

				

				</p>
<p><span class="Bold">Clotrimazole:</span> Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment
of dermal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by various species of pathogenic dermatophytes and yeasts. The
primary action of clotrimazole is against dividing and growing organisms.<br><span class="Italics">In vitro,</span> clotrimazole exhibits fungistatic and fungicidal activity against isolates of <span class="Italics">Trichophyton
rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>
spp., and <span class="Italics">Malassezia pachydermatis (Pityrosporum canis).</span> Resistance to clotrimazole is very				
rare among the fungi that cause superficial mycoses.<br>
In an induced <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> infected with <span class="Italics">Malassezia pachydermatis,</span> 1% clotrimazole in the
Vetromax ointment vehicle was effective both microbiologically and clinically in terms of
reduction of exudate odor and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.<br>
In studies of the mechanism of action, the minimum fungicidal concentration of clotrimazole
caused leakage of intra-cellular phosphorus compounds into the ambient medium with
concomitant breakdown of cellular nucleic acids and accelerated potassium efflux. These events
began rapidly and extensively after addition of the drug.<br>
Clotrimazole is very poorly absorbed following dermal application.
				</p>
<p><span class="Bold">Gentamicin-Betamethasone-Clotrimazole:</span> By virtue of its three active ingredients,
Vetromax ointment has antibacterial, anti-inflammatory, and antifungal activity.<br>
In component efficacy studies, the compatibility and additive effect of each of the components
were demonstrated. In clinical field trials, gentamicin sulfate, betamethasone valerate, and
clotrimazole ointment was effective in the treatment of <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> associated with bacteria and
<span class="Italics">Malassezia pachydermatis.</span> Gentamicin sulfate, betamethasone valerate, and clotrimazole
ointment reduced <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, exudate, and odor, and exerted a strong
antimicrobial effect.				

				</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS:</h1>
<p class="First">
Vetromax ointment is indicated for the treatment of canine acute and chronic
<span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> associated with yeast <span class="Italics">(Malassezia pachydermatis,</span> formerly <span class="Italics">Pityrosporum canis)</span>
and/or bacteria susceptible to gentamicin.
			</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">
If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components occurs, treatment
should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to
induce <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> should be avoided. Do not use in dogs with known perforation of eardrums.
			</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">
The use of gentamicin sulfate, betamethasone valerate, and clotrimazole ointment
has been associated with <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> or partial <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> in a small number of sensitive dogs
(e.g. geriatric). The hearing deficit is usually temporary. If hearing or vestibular dysfunction is
noted during the course of treatment, discontinue use of Vetromax ointment immediately and
flush the ear canal thoroughly with a nonototoxic solution.<br>
Corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in
<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in offspring. Other congenital anomalies including deformed forelegs, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>,
and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> have been reported in offspring of dogs which received corticosteroids during
pregnancy.<br>
Clinical and experimental data have demonstrated that corticosteroids administered orally or
parenterally to animals may induce the first stage of parturition if used during the last trimester of
pregnancy and may precipitate premature parturition followed by dystocia, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, retained
placenta, and metritis.
			</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PC"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">
Identification of infecting organisms should be made either by microscopic roll
smear evaluation or by culture as appropriate. Antibiotic susceptibility of the pathogenic
organism(s) should be determined prior to use of this preparation.
If overgrowth of nonsusceptible bacteria, fungi, or yeasts occur, or if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> develops,
treatment should be discontinued and appropriate therapy instituted.<br>
Administration of recommended doses of Vetromax ointment beyond 7 days may result in
delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.<br>
Avoid ingestion. Adverse systemic reactions have been observed following the oral ingestion of
some topical corticosteroid preparations. Patients should be closely observed for the usual signs
of adrenocorticoid overdosage which include <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>,
<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, and/or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>. Prolonged use or overdosage may produce adverse
immunosuppressive effects.<br>
Use of corticosteroids, depending on dose, duration, and specific steroid, may result in
endogenous steroid production inhibition following drug withdrawal. In patients presently
receiving or recently withdrawn from corticosteroid treatments, therapy with a rapidly-acting
corticosteroid should be considered in especially stressful situations. Before instilling any
medication into the ear, examine the external ear canal thoroughly to be certain the tympanic
membrane is not ruptured in order to avoid the possibility of transmitting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the middle
ear as well as damaging the cochlea or vestibular apparatus from prolonged contact.
			</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1>TOXICOLOGY:</h1>
<p class="First">
Clinical and safety studies with gentamicin sulfate, betamethasone valerate,
and clotrimazole ointment have shown a wide safety margin at the recommended dose level in
dogs (see <a href="#PC">PRECAUTIONS</a>/<a href="#SE">SIDE EFFECTS</a>).
			</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="SE"></a><a name="section-10"></a><p></p>
<h1>SIDE EFFECTS:</h1>
<p class="First"><span class="Bold">Gentamicin: </span>While aminoglycosides are absorbed poorly from skin, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> may occur
when aminoglycosides are applied topically for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time to large <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>,
or any denuded skin, particularly if there is <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. All aminoglycosides have the
potential to produce reversible and irreversible vestibular, cochlear, and renal toxicity.

			</p>
<p><span class="Bold">Betamethasone: </span>Side effects such as SAP and SGPT enzyme elevations, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>,
<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> have occurred following the use of parenteral or systemic
synthetic corticosteroids in dogs. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occasionally bloody) have been
observed in dogs and cats.<br>
Cushing's syndrome in dogs has been reported in association with prolonged or repeated
steroid therapy.
			</p>
<p><span class="Bold">Clotrimazole: </span>The following have been reported occasionally in humans in connection with
the use of clotrimazole: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and
general irritation of the skin not present before therapy.
			</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">

The external ear should be thoroughly cleaned and
dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable
non-irritating solutions. Excessive hair should be clipped from the treatment area. After verifying
that the eardrum is intact, instill 4 drops from the 7.5 g and 15 g tube of Vetromax twice daily
into the ear canal of dogs weighing less than 30 lbs. Instill 8 drops from the 7.5 g and 15 g tube
twice daily into the ear canal of dogs weighing 30 lbs. or more. Massage external ear canal
carefully after instillation to ensure appropriate distribution of medication. Therapy should
continue for 7 consecutive days.

			</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">
Vetromax ointment is available in:
			</p>
<p>
7.5 g NDC 17033-282-75 tubes<br>
15 g NDC 17033-282-15 tubes<br>
215 g NDC 17033-282-24 tubes
			</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<h1>STORAGE:</h1>
<p class="First">
Store between 2° and 25°C (36° and 77°F).<br>
Shake well before use when using the 215g bottle.
			</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1>TO OPEN:</h1>
<p class="First">
			Use cap to puncture seal.
                  </p>
<p><img alt="image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-01.jpg"></p>
<p>
1. Remove entire Applicator Assembly,
puncture tube with white portion of the cap.
                  </p>
<br><br><p><img alt="image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-02.jpg"></p>
<p>
2. Replace entire
Applicator Assembly.
                  </p>
<br><br><p><img alt="image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-03.jpg"></p>
<p>
3. To dispense, remove the
white portion of the cap.
                  </p>
<br><br><p><img alt="image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-04.jpg"></p>
<p>
4. After use replace
white cap to close.
                  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1>IMPORTANT:</h1>
<p class="First">
			The opening of this product is covered by a metal tamper-resistant seal.
                  </p>
<p>
	If this seal has been punctured or is not visible, do not use and return product to place of
purchase.
                  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MANUFACTURED FOR:</span><br>
Dechra Veterinary Products, Overland Park, KS 66211<br></p>
<p>
I282/IF282 DECHRA R07/08 #256
                  </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7.5 g Carton</h1>
<p class="First"><span class="Bold">VETROMAX<span class="Sup">®</span></span><br>
				gentamicin sulfate USP, <br>betamethasone valerate USP <br>and clotrimazole USP ointment<br><span class="Bold">NET WT 7.5 g (1/4 oz)</span><br><span class="Bold">ANADA</span> # 200-283. Approved by FDA<br><span class="Bold">NDC</span> 17033-282-75<br></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 7.5 g Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-05.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7.5 mL Container</h1>
<p class="First"><span class="Bold">NET CONTENTS 7.5 g (1/4 oz)</span><br><span class="Bold">NDC</span> 17033-282-75<br><span class="Bold">VETROMAX<span class="Sup">®</span></span><br>
				gentamicin sulfate USP, betamethasone <br>valerate USP and clotrimazole USP ointment<br><span class="Bold">ANADA</span> # 200-283. Approved by FDA.<br></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 7.5 mL Container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e87e215f-f342-4f19-a4f6-e80c8cf51587&amp;name=vetro-max-ointment-06.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETROMAX 		
					</strong><br><span class="contentTableReg">gentamicin sulfate, betamethasone valerate and clotrimazole ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17033-282</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">AURICULAR (OTIC)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GENTAMICIN SULFATE</strong> (GENTAMICIN) </td>
<td class="formItem">GENTAMICIN</td>
<td class="formItem">3 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BETAMETHASONE VALERATE</strong> (BETAMETHASONE) </td>
<td class="formItem">BETAMETHASONE VALERATE</td>
<td class="formItem">1 mg  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOTRIMAZOLE</strong> (CLOTRIMAZOLE) </td>
<td class="formItem">CLOTRIMAZOLE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17033-282-75</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">7.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17033-282-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">15 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:17033-282-24</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">215 g in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANADA</td>
<td class="formItem">ANADA200283</td>
<td class="formItem">06/01/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dechra Veterinary Products
							(362142734)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Fougera Pharmaceuticals Inc. (043838424)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cae2cf4b-001c-4ab6-b1aa-28b08ccd22b9</div>
<div>Set id: e87e215f-f342-4f19-a4f6-e80c8cf51587</div>
<div>Version: 2</div>
<div>Effective Time: 20130207</div>
</div>
</div> <div class="DistributorName">Dechra Veterinary Products</div></p>
</body></html>
